• Consensus Rating: Buy
  • Consensus Price Target: $0.85
  • Forecasted Upside: 58.94 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.53
▼ -0.02 (-3.60%)

This chart shows the closing price for MRMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MariMed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRMD

Analyst Price Target is $0.85
▲ +58.94% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for MariMed in the last 3 months. The average price target is $0.85, with a high forecast of $0.85 and a low forecast of $0.85. The average price target represents a 58.94% upside from the last price of $0.53.

This chart shows the closing price for MRMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in MariMed.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/12/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/12/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/7/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/28/2022BTIG ResearchInitiated CoverageBuy$0.85
3/22/2022Colliers SecuritiesReiterated RatingBuy
3/4/2022Echelon Wealth PartnersReiterated RatingSpeculative Buy
9/15/2021Colliers SecuritiesInitiated CoverageBuy$2.25
(Data available from 12/7/2017 forward)

News Sentiment Rating

1.22 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/11/2022
  • 4 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/10/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2022
  • 8 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
8/9/2022
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/8/2022
  • 3 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/8/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/7/2022
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2022

Current Sentiment

  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

MariMed logo
MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company offers cannabis genetics produce flowers and concentrates under the Nature's Heritage brand; cannabis-infused products in the form of chewable tablets and powder drink mixes under the brand Kalm Fusion; natural fruit chews under the Betty's Eddies brand; brownies, cookies, and other social sweets under the Bubby's Baked brand; and cannabidiol formulations under the Florance brand. It also licenses its brands and product formulations, as well as leases cannabis facilities. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.
Read More

Today's Range

Now: $0.53
Low: $0.50
High: $0.56

50 Day Range

MA: $0.53
Low: $0.41
High: $0.65

52 Week Range

Now: $0.53
Low: $0.40
High: $0.94

Volume

415,579 shs

Average Volume

299,422 shs

Market Capitalization

$181.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.22

Frequently Asked Questions

What sell-side analysts currently cover shares of MariMed?

The following Wall Street sell-side analysts have issued stock ratings on MariMed in the last year: BTIG Research, Colliers Securities, and Echelon Wealth Partners.
View the latest analyst ratings for MRMD.

What is the current price target for MariMed?

1 Wall Street analysts have set twelve-month price targets for MariMed in the last year. Their average twelve-month price target is $0.85, suggesting a possible upside of 58.9%. BTIG Research has the highest price target set, predicting MRMD will reach $0.85 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $0.85 for MariMed in the next year.
View the latest price targets for MRMD.

What is the current consensus analyst rating for MariMed?

MariMed currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MRMD will outperform the market and that investors should add to their positions of MariMed.
View the latest ratings for MRMD.

What other companies compete with MariMed?

Other companies that are similar to MariMed include Ayr Wellness, Valens, ChromaDex, HEXO and Bright Green. Learn More about companies similar to MariMed.

How do I contact MariMed's investor relations team?

MariMed's physical mailing address is 11 ROYAL ROAD, BROOKLINE MA, 02445. The company's listed phone number is (617) 795-5140 and its investor relations email address is [email protected] The official website for MariMed is marimedadvisors.com. Learn More about contacing MariMed investor relations.